Goodwin Procter advised Toast, Inc. on the deal while Sullivan & Cromwell represented the underwriters. Toast, Inc. (NYSE: TOST) announced its initial public offering of 25,000,000 shares...
Toast’s $1.0 Billion IPO
G Squared Ascend I’s Business Combination Agreement with Transfix
Goodwin Procter advised G Squared Ascend I on the deal. Latham & Watkins represented Transfix. G Squared Ascend I (NYSE: GSQD), a special purpose acquisition company...
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
Pfizer’s $2.26 Billion Acquisition of Trillium Therapeutics
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Cambridge Mobile Telematics’ Acquisition of TrueMotion
Goodwin Procter LLP advised TrueMotion on the deal. TrueMotion announced its acquisition by Cambridge Mobile Telematics. The transaction, which closed on June 16, unites the two leading...
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Aerpio Pharmaceuticals’ Merger with Aadi Bioscience
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
Privia Health Group’s $607.8 IPO
Goodwin Procter LLP advised the underwriters on the deal. Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with...
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
Century Bancorp’s $642 Million Merger Agreement with Eastern Bankshares
Goodwin Procter LLP advised Century Bancorp, Inc. on the deal, while Simpson Thacher advised J.P. Morgan Securities LLC as financial advisor to Eastern Bankshares. Century Bancorp,...